الفهرس 
Thalassemia MajorOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
The Aim of this study was to assess the level of 25 hydroxy vitamin D and bone mineralization status in β-thalassemic patients and its relation to different types of chelation therapies to compare the effect of conventional chelators versus recent oral chelators on bone mineralization status.
Methods:
Our study included 45 patients with β-thalassemia major who were following up regularly in the Pediatric Hematology clinic of the Pediatric Hospital, Ain Shams University. 15 patients were on desferrioxamine,15 patients were on deferiprone and 15 patients on deferasirox. They were compared with 15 age and sex matched, healthy children and adolescents controls. All were subjected to full history taking and thorough clinical examination with stress on: age at diagnosis, frequency of blood transfusion, splenectomy, chelation therapy, and bone related symptoms and signs. Complete blood count as well as, levels of 25-OH-vit D,calcium, serum phosphate, alkaline phosphatase and Serum ferritin were estimated.
Results:
In our study, the serum calcium level and serum 25 –OH-vit D levelwere significantly lower in our patients than that of controls, 70 % of patients had low serum 25 –OH-vit D level while the remaining patients(30%) had normal levels. There was no significant difference between patients and controls in phosphorous level. The serum alkaline phosphatase level was significantly higher in our patients than that of controls. Our study populations were moderate to severely iron overloaded. 25 (OH) vit D correlated proportionately with serum calcium; and inversely with serum ferritin. No significant difference in effects of subcutaneous desferrioxamine (DFX) and oral deferiprone (L1),deferasirox chelation therapies on 25-OH-vit D level and bone metabolism markers in patients with thalassemia major.
Conclusion:
-High prevalence of vit. D deficiency and iron overload were detected in thalassemic patients that may largely contribute to their bone diseases. -There was no significant difference in the effect of sc. Chelators and oral chelators on bone markers and 25 –OH- VitD.